Table 3.
Factors associated with significant liver fibrosis in HIV-infected patients attending referral HIV clinics in Abidjan, Dakar and Lome, West Africa (n = 807)
| Univariate analysis |
Multivariable analysis |
||||
|---|---|---|---|---|---|
| n/N | OR (95% CI) | p | OR (95% CI) | p | |
| Age | 0.15 | 0.11 | |||
| ≤40 years >40 years |
12/313 31/494 |
1 1.6 (0.8–3.2) |
1 1.8 (0.9–3.6) |
||
| Gender | <0.01 | 0.07 | |||
| Women Men |
22/570 21/237 |
1 2.4 (1.3–4.5) |
1 1.8 (0.9–3.5) |
||
| Referral hospital | 0.02 | 0.04 | |||
| Dakar, Senegal Abidjan, Côte d’Ivoire Lome, Togo |
3/211 20/348 20/248 |
1 3.7 (1.2–11.7) 5.3 (1.7–16.9) |
1 3.6 (1.2–11.3) 4.6 (1.4–15.2) |
||
| Alcohol use, | <0.0001 | <0.01 | |||
| AUDIT-c scorea <4b ≥4–5 ≥6 |
25/536 11/237 7/34 |
1 0.7 (0.1–3.9) 8.4 (3.6–19.5) |
1 0.5 (0.1–2.5) 4.3 (1.7–10.8) |
||
| Antigen HBsc | 0.07 | 0.04 | |||
| Negative Positive |
36/733 7/74 |
1 2.1 (0.9–4.9) |
1 2.5 (1.1–6.1) |
||
| Anti-HCV antibodyd | 0.02 | 0.11 | |||
| Negative Positive |
41/798 2/9 |
1 6.1 (1.3–28.4) |
1 4.8 (0.8–27.4) |
||
| Antiretroviral use | 0.05 | 0.21 | |||
| ≤1 >1–5 >5 |
16/186 16/304 11/317 |
1 0.6 (0.3–1.2) 0.4 (0.2–0.8) |
1 0.7 (0.3–1.5) 0.5 (0.2–1.1) |
||
n/N: number of HIV-infected patients with significant fibrosis /total number of HIV-infected patients for a specific category.
aDeclared alcohol use during the last 12 month scored with the short version of the alcohol use disorders identification test (AUDIT-c).
b<3 for women.
cAssessed with a rapid diagnostic test: Determine® (Alere, Waltham, MA, USA).
dAssessed with a rapid diagnostic test: Oraquick® (Orasure, Bethlehem, PA, USA).
HIV: human immunodeficiency syndrome; HCV: hepatitis C virus; OR: odd ratio; CI: confidence interval.